A biochemical approach was used to identify proteins which interact with human BRCA1. Through this work, a kinase activity which co-puri®es with BRCA1 has been identi®ed. This kinase activity, which phosphorylates BRCA1 in vitro, was originally identi®ed in Sf9 insect cells but is also present in cells of human origin including breast and ovarian carcinoma cell lines. The BRCA1 kinase activity in vitro is associated with a fragment of BRCA1 encompassing amino acids 329 ± 435. This peptide is also phosphorylated in various human cell lines. A computer-assisted sequence analysis revealed that this peptide was a potential substrate for phosphorylation by PKA, PKC, or CKII. However, phosphorylation by these kinases could not be demonstrated in vitro indicating the presence of another kinase activity. Phosphorylation in vitro requires a minimal domain of BRCA1 encompassing amino acids 379 ± 408. Notably, deletion of this minimal domain abolishes growth suppression by BRCA1 indicating that this domain, as well as phosphorylation within this domain, may be important for BRCA1 function.
Introduction
BRCA1 is a gene discovered as a result of a search that was focused on identifying speci®c genes in which mutation or loss confer an increased susceptibility to breast cancer . Studies conducted to date show that mutations in BRCA1 occur frequently in families demonstrating a high incidence of breast and/or ovarian cancer (Castilla et al., 1994; Miki et al., 1994; Friedman et al., 1994; Shattuck-Eidens et al., 1995; Simard et al., 1994) . Notably, women within such families who develop cancer all have inherited the mutant allele and have also acquired a somatic mutation aecting the other allele (Castilla et al., 1994; Merajver et al., 1995; Smith et al., 1992) . These data indicate that BRCA1 is a tumor suppressor gene. In support of these data, are studies which show that the introduction of BRCA1 into breast tumor cells results in growth suppression both in vitro and in vivo . These results correlate well with studies that show accelerated growth and transformation in cells expressing BRCA1 antisense RNA (Rao et al., 1995; Thompson et al., 1995) . In contrast, human genetic studies, which have evaluated the occurrence of BRCA1 mutations in sporadic (non-familial) cancers, indicate that such mutations are rarely observed in individuals who are not within high risk families Hosking et al., 1995; Merajver et al., 1995) . Thus while it appears that mutations in BRCA1 can contribute to cancer, the relative importance of this gene in the development of a large number of sporadic cancers has yet to be recognized (Boyd, 1995; Vogelstein and Kinzler, 1994) .
Equally enigmatic is the role that BRCA1 plays in normal growth and development. Analysis of the BRCA1 protein provides only a limited insight into its function since the protein does not share extensive homology with other known proteins. However, there are short regions within BRCA1 that share homology with speci®c functional domains. The most obvious is the zinc ring ®nger located at the extreme aminoterminus (amino acids 23 ± 71) . The conservation of the ring ®nger domain across species as well as the relative abundance of mutations in this region suggest that this domain is indeed important for BRCA1 activity (Bienstock et al., 1996; Szabo et al., 1996) . Moreover, the presence of the ring ®nger together with two nuclear localization signals (Thakur et al., 1997) , and a putative C-terminal transactivation domain, (Chapman and Verma, 1996; Monteiro et al., 1996) supports the notion that BRCA1 may be a transcription factor. While nuclear localization of BRCA1 has been demonstrated Scully et al., 1996; Thakur et al., 1997; Thomas et al., 1996) , direct sequence-speci®c DNA binding by BRCA1 has not. Similarly, evidence demonstrating transactivation of a speci®c cellular gene by BRCA1 is lacking. A putative granin motif located between amino acids 1214 and 1223 has also been identi®ed; the presence of which suggests a possible role for BRCA1 in regulated secretion .
Biochemical studies indicate that BRCA1 is regulated in a cell cycle dependent fashion. This cycledependent regulation occurs both transcriptionally and post transcriptionally. Speci®cally, the levels of BRCA1 mRNA and protein increase as cells progress from G1 to S (Chen et al., 1996; Gudas et al., 1996; Vaughn et al., 1996) . This increase in protein expression at G1/S is concomitant with an increase in phosphorylation. Such phosphorylation may be mediated by cdk 2 or kinases that associate with cyclins D or A (Chen et al., 1996) . Thus, the eects of BRCA1 on growth may be mediated through an interaction with components of the cell cycle machinery.
Biological studies involving gene knockouts show that BRCA1 is essential for mouse development since homozygous knockout mice die in utero (Gowen et al., 1996; Hakem et al., 1996) . Such studies again show a relationship between BRCA1 and growth regulation. In support of this are studies in mouse embryos that show BRCA1 expression is highest in actively proliferating tissues or in tissues undergoing differentiation (Lane et al., 1995; Marquis et al., 1995) .
The above studies clearly indicate the importance of BRCA1 in growth and development. However, the mechanisms by which BRCA1 in¯uences these events are not understood. Moreover, no clear relationship between BRCA1 mutation and the development of cancer has emerged. In particular, there are no obvious explanations for why mutations in BRCA1 are rarely observed in sporadic disease. Further understanding of these issues requires more knowledge about the regulatory pathways in which BRCA1 participates. Accordingly, we have focused our studies on identifying proteins that interact with BRCA1. We report here a kinase activity that co-puri®es with BRCA1 and catalyzes its phosphorylation. In addition, we show that this kinase activity may be important for BRCA1 function since deletion of the region of phosphorylation within BRCA1 abolishes its growth suppressor activity.
Results
Initial experiments were aimed at evaluating whether BRCA1 was phosphorylated in breast cell lines. In these studies, either MCF-7 or 184-A1 cells were incubated with [ 32 P]orthophosphate. Lysates were then prepared, and subsequently subjected to immunoprecipitation using control antibodies or antibodies directed against BRCA1. The results in Figure 1 show that BRCA1 is indeed phosphorylated in breast cell lines since a radiolabeled protein of *210 KDa is evident only in immunoprecipitates using anti-BRCA1 antibodies.
Subsequent studies were directed towards identifying the regions of BRCA1 which serve as substrates for phosphorylation as well as identifying speci®c kinases involved in this activity. One approach we took involved expressing various fragments of BRCA1 in Sf9 insect cells as GST fusion proteins. These fragments were puri®ed over glutathione agarose and Figure 2 A kinase activity from insect cells copuri®es with BRCA1. Proteins used in this assay were expressed in Sf9 insect cells using a baculovirus-based expression system. The expressed proteins included a GST fusion protein, denoted as B63, which includes amino acids 329 ± 629 from BRCA1 (lane 1), GST alone (lane 2), B73 which is the same as B63 but lacks GST (lane 3), and full-length BRCA1 (lane 4). Sf9 cells expressing these proteins were lysed and the proteins were captured using either glutathione-Sepharose-4B or protein G-agarose bound with BRCA1 antibody. The immobilized proteins were incubated with g-AT
32
P and then analysed for phosphorylation by SDS ± PAGE BRCA1 phosphorylation TF Burke et al subsequently evaluated for the presence of kinase activity. In this search, we identi®ed one fragment encompassing BRCA1 amino acids 329 ± 629 that appeared to have an associated kinase activity. Figure  2 shows that this fragment, denoted as B63, is phosphorylated in vitro when incubated in the presence of g-AT
P alone. No such phosphorylation was observed when insect cell derived GST was used as a substrate, indicating that kinase activity was associated with BRCA1 and not with GST. The results using constructs that lack GST support this conclusion. Speci®cally, lanes 3 and 4 in Figure 2 show that both B73, a derivative of B63 without a GST tag, and full-length BRCA1 were phosphorylated when incubated with g-AT
P. Not all regions of BRCA1, when tested in vitro, showed kinase activity (data not shown), indicating that this activity is speci®c for B63 and is not an in vitro artifact. The regions that were not phosphorylated in vitro included the ring-®nger region de®ned by amino acids 1 ± 180 and a extreme Cterminal domain de®ned by amino acids 1662 ± 1863.
The results of the above experiments suggested that BRCA1 may be a kinase capable of autophosphorylation. Alternatively the results also indicated that a kinase physically associates with BRCA1 and that this kinase remains associated throughout the puri®cation procedure. A computer-assisted sequence analysis does not support the ®rst alternative since hallmarks associated with known kinases were not detected in the BRCA1 sequence. In addition, experiments directed at detecting autophosphorylation showed no such activity (data not shown). Thus it seemed plausible to us that the phosphorylation we detected was due to a kinase which was physically bound to BRCA1. The results presented in Figure 3 supported this hypothesis since treatment of B63 with 0.1% SDS prior to the addition of ATP destroyed all kinase activity. However, incubation of the SDS washed B63 with crude lysates from Sf9 cells restored kinase activity (compare Figure 3a and b) . Notably, this kinase activity could also be restored by incubating B63 with crude lysates from human breast and ovarian cell lines including MCF-7, 184-A1 (Figure 3b ) and A2780 (data not shown). Further studies showed that incubation of crude Sf9 or MCF-7 lysates with 0.1% SDS prevented these lysates from restoring kinase activity to SDSwashed B63 (data not shown), thereby indicating that the kinase activity was associated with the crude lysates and was not an integral part BRCA1. These results were supported by studies which showed that the kinase activity could be depleted from crude lysates by repeated incubations with SDS-washed B63 (data not shown).
Computer-assisted sequence analysis indicated the presence of potential acceptor sites for phosphorylation by cAMP-dependent kinase (PKA), casein kinase II (CKII), and protein kinase C (PKC) (see Figure 4) . The results in Figure 5 showed that neither PKA (lane 3) nor PKC (lane 4) phosphorylated B63 (the radiolabeled band that appears in lane 3 in autophosphorylated PKA and not BRCA1). Only minor phosphorylation of B63 was observed with CKII (lane 5). These data suggested that neither PKA, PKC, nor CKII were responsible for the strong in vitro phosphorylation detected in the previous experiments. Although minor phosphorylation of B63 by CKII was observed, subsequent control experiments which included heparin or excess unlabeled GTP (an alternative phosphate donor for CKII) did not inhibit the in vitro phosphorylation of B63, indicating that CKII probably was not responsible for such activity (data not shown). Cyclin D1/cdk4, cyclinE/cdk2, raf kinase, and SAPK/Jun kinase were also evaluated and none were found to phosphorylate B63 when assayed by the conditions outlined in Figure 1 (data not shown).
A deletion analysis of B63 ( Figure 6 ) showed that phosphorylation by the BRCA1-associated kinase required the ®rst *100 amino acids of this peptide (i.e. BRCA amino acids 329 ± 435). Deletion between amino acids 421 and 433 did not aect phosphorylation, indicating that loss of the single tyrosine within B63 was unimportant. Deletion analysis also showed that phosphorylation required the presence of the domain between amino acids 379 ± 389 ( Figure 6 ).
Further de®nition of the region of phosphorylation was approached using a smaller fragment of B63 denoted as B71 (amino acids 329 ± 435). Biochemical studies showed that this fragment eluted as single peak after alkaline phosphatase treatment, and as two peaks after incubation with g-AT 33 P (Figure 7a) . One of these peaks eluted with phosphatase-treated B71 whereas the other eluted earlier and corresponded phosphorylated B71. Subsequent analysis which included tryptic digestion and HPLC puri®cation of the resultant tryptic fragments showed that phosphorylation, as measured by elution of incorporated 33 P label, was associated with a single tryptic peptide (Figure 7b and c). Sequencing showed that this peptide was derived from amino acids 389 ± 408 which is immediately adjacent to the domain de®ned by the deletion studies described above (amino acids 379 ± 389).
The experiments on in vitro phosphorylation were followed by cell-based studies evaluating phosphorylation in human cells. WI-38 ®broblasts or A2780 ovarian cells were transfected with a construct expressing a fusion protein between B71 and S-protein. The transfected cells were incubated with [ 32 P]orthophosphate and lysates were prepared. The S/ B71 fusion proteins were subsequently captured from the lysates using S-agarose. A 32 P-labeled protein of the appropriate molecular weight was precipitated by Sagarose in cells transfected with the S/B71 construct but not in cells transfected with a control vector (Figure 8a and b). Moreover, a radiolabeled band was detected in WI-38 ®broblasts transfected with a doxycyclinerepressible S/B71 fusion protein when such transfected cells were grown in the absence but not in the presence of doxycycline (Figure 8a ). Overall, these data indicate that the region of BRCA1 encoded by B71 (amino acids 329 ± 435) is phosphorylated in human cells.
Previous studies have shown that transfection of full-length BRCA1 into human tumor cells results in growth suppression . A similar result Deletion mapping de®nes the region required for phosphorylation. Various deletions in B63 were created and expressed in Sf9 cells as fusion proteins with GST. These proteins were isolated as described in Figure 2 and incubated with g-AT 32 P. Those fragments that served as substrates for in vitro phosphorylation are indicated by (+). Those that showed little (410-fold) or no phosphorylation are indicated by (7) is presented in Figure 9 . Signi®cant growth suppression, as measured by a decrease in formation of G418 resistant colonies, was observed in A2780 ovarian carcinoma cells transfected with full-length BRCA1 compared to the same cells transfected with a control vector. Notably, growth suppression by BRCA1 is lost in mutants which have a deletion between amino acids 329 ± 435 or a much smaller deletion encompassing the minimal phosphorylation domain described above (D379 ± 408). Figure 10 shows that the wt-BRCA1 transgene as well as both deletion mutants are expressed in A2780 following transfection. Identical results were achieved when OvCar3 ovarian carcinoma cells were used instead of A2780 (data not shown).
Discussion
Research on BRCA1 over the past 2 years has been focused toward understanding its function. In this regard, studies have been aimed at not only understanding the role of BRCA1 in normal cell physiology but also toward clarifying the extent to which it plays a role in cancer development. Accordingly, we and others have looked for proteins which associate with BRCA1 as an approach to identify regulatory pathways in which it participates. Previous studies by Lee and colleagues have shown that BRCA1 is phosphorylated and that some of this phosphorylation may be potentially mediated by cyclin-dependent kinases (Chen et al., , 1996 . These studies as well as others suggest a linkage between BRCA1 phosphorylation and cell cycle progression (Thomas et al., 1997) . The studies presented here also show that BRCA1 exists as a phosphoprotein in breast cell lines. These studies additionally demonstrate that a kinase other than a cyclin-dependent kinase copuri®es with BRCA1 and that this kinase catalyzes the phosphorylation of BRCA1 in vitro. Notably, through this work, we were able to identify for the ®rst time a speci®c domain within BRCA1 that is phosphorylated. Furthermore, we showed that this domain is potentially important for the regulation of cell growth since deletion of this region resulted in a loss of growth suppression.
The kinase described in this report was originally identi®ed in lysates prepared from insect cells as a kinase that associates with and phosphorylates a region of exon 11 encompassing amino acids 329 ± 629. We subsequently showed that this kinase is also present in human cells. Interestingly, the region that was identi®ed is one region within BRCA1 that contains a number of putative phosphorylation sites including sites for PKA, PKC and CKII. When tested in vitro, the kinase activity toward BRCA1 that was detected with either PKA, PKC or CKII was well below the activity detected with the exon 11 fragment alone. The low activity shown by these three kinases under P. Phosphorylated and unphosphorylated forms of B71 were separated by reverse phase HPLC. (b) Phosphorylated B71 was digested with trypsin and the resultant tryptic peptides were puri®ed by HPLC. The identity of the peptides in each peak was con®rmed by sequencing. (c) Fractions from the elution described in b were quanti®ed for radioactivity. Only one peak was found to contain any radiolabel. This peak is indicated by the arrow in b conditions where signi®cant BRCA1-associated kinase activity could be detected suggests that the exon 11 associated kinase is not PKA, PKC or CKII. However, these data do not necessarily imply that PKA, PKC and CKII are incapable of phosphorylating BRCA1 in vitro or in vivo since our assay was not optimized to evaluate phosphorylation by these speci®c kinases.
Results from recent studies suggest that BRCA1 phosphorylation is enhanced by treatments that either damage DNA or induce cell stress (Thomas et al., 1997) . Accordingly, we evaluated whether the region between amino acids 329 ± 435 (B71) could be phosphorylated in vitro by stress-activated kinases. No phosphorylation of the B71 fragment was evident when this fragment was incubated with SAPK/jun kinase. Moreover, no enhancement of in vitro phosphorylation was observed when lysates from u.v.-irradiated cells were used as the source of the kinase instead of untreated control cells (data not shown).
The possibility that BRCA1 itself is an autokinase was eliminated by studies which showed that the kinase activity could be separated from BRCA1 by incubation with 0.1% SDS. Furthermore, this kinase activity was restored to BRCA1 by incubating it with lysates from human cells. These results were supported by studies which showed that BRCA1 kinase activity could be depleted from cell lysates by repeated incubations with fragments of GST-BRCA1 but not with GST alone (data not shown). Gel overlay assays were also used to evaluate the potential for autophosphorylation. These assays, which involved electrophoretic separation of BRCA1, in situ renaturation and subsequent incubation with g-AT 32 P, showed no phosphorylation of BRCA1 (data not shown). Thus, these studies like those discussed above indicate that it is unlikely that BRCA1 is an autokinase. A ®nal set of experiments showed that BRCA1 could only be radiolabeled when incubated with g-AT
32
P but not with a-AT 32 P, thereby indicating that BRCA1 is not an ATP binding protein.
Taken together, these studies are supportive of the notion that the kinase activity associated with BRCA1 is a separate entity from BRCA1. Thus, the phosphorylation observed in this study appears to be a consequence of a physical association between BRCA1 and an unknown kinase. Discovery of a BRCA1-associated kinase has important implications for studies evaluating whether a speci®c kinase of interest has potential to phosphorylate BRCA1. Clearly signi®cant phosphorylation of BRCA1, as were transfected with empty vector or with a vector construct expressing a fusion protein between S-protein and the B71 fragment from BRCA1. The transfected cells were labeled with 32 P-orthophosphate and lysates were prepared. S/B71 fusion proteins were captured on S-agarose, and analysed by SDS ± PAGE and autoradiography. Shown in a are the proteins that were captured from WI-38 ®broblasts transfected with the S/B71 fusion construct (lanes 1 ± 4) or with empty vector (lanes 5 and 6). Cells were grown either in the presence (+) or absence (7) of 10 ng/ml doxycycline. Shown in b are the proteins precipitated from A2780 cells transfected with either a vector control (lane 7) or the S/B71 construct (lane 8). The position of the phosphorylated S/B71 protein is indicated by the arrow demonstrated by the studies presented here, can occur in the absence of an added kinase. This phosphorylation can thereby obscure the results that may be obtained with speci®c kinases of interest.
The work described here has been primarily focused on understanding whether phosphorylation catalyzed by the BRCA1-associated kinase is biologically relevant. In this regard, we have attempted to de®ne the sites phosphorylated by the kinase and how alterations at these sites aect growth suppression by BRCA1. This work was approached by both deletion and biochemical analyses. Deletion studies were undertaken since kinase activity was originally shown to be associated with a rather large region of BRCA1 (amino acids 329 ± 629). This region contained 33 serines, 15 threonines and two tyrosines. The region also potentially contained three PKA sites, six PKC sites, and six CKII sites. Fragmentation of this region indicated that only the 5' third of this region, namely amino acids 329 ± 435 was essential for phosphorylation. Removal of amino acids 422 ± 435 did not eect phosphorylation, indicating that phosphorylation did not require tyrosine. Further deletion identi®ed a region from 379 ± 389 that was essential for kinase activity. This region contained two serine residues one of which was part of a predicted CKII site.
Biochemical studies, which involved in vitro phosphorylation followed by trypsin digestion, revealed only one phosphate-containing tryptic peptide. This peptide, which encompassed amino acids 389 ± 408, contained ®ve serines, one of which (Ser 389 ) was the only amino acid that overlapped with the essential domain identi®ed by the deletion studies. Mutation of Ser 389 to alanine did not reduce phosphorylation of the B71 fragment (amino acids 329 ± 435), indicating that this serine is either not a site for phosphorylation or that it represents only one site within a family of sites encompassed between residues 389 and 408 (data not shown). Mutations (all serine to alanine) were then introduced separately into each serine within the domain de®ned between amino acids 389 ± 408. Curiously, none of the single missense mutations aected phosphorylation of the B71 fragment (data not shown). These data again suggest the possibility that either more than one serine within the fragment can be phosphorylated or that there may be a preferred site for phosphorylation, but other secondary sites may serve as substrates in vitro when the preferred site is lost.
One site of phosphorylation clearly occurs on the tryptic fragment de®ned by amino acids 389 and 408. The region upstream of this fragment may facilitate or stabilize binding of the kinase since the deletion analyses indicated that this region was also important for in vitro kinase activity. Thus, we have de®ned the minimal domain as the region between amino acids 379 and 408 since this region encompasses both the domains de®ned by the deletion studies and the biochemical analysis.
Subsequent experiments were focused on demonstrating whether phosphorylation by the BRCA1-associated kinase was biologically relevant. Initial experiments with A2780 and WI-38 cells showed that B71 (amino acids 329 ± 435) was a target for intracellular phosphorylation. This indicated that phosphorylation within this region was not an in vitro shows a control PCR reaction in which vector DNA containing wild-type BRCA1 was used as a template. Lane 2 shows an additional control in which no DNA was included in the PCR reaction. In cells transfected with wt-BRCA1 (lanes 3 and 4), BRCA1-D329 ± 435 (lanes 5 and 6), or BRCA1-D379 ± 408 (lanes 7 and 8), a 412 bp BRCA1-speci®c DNA fragment (indicated by arrow) is ampli®ed only in samples where the reverse transcription reaction was performed (lanes 3, 5 and 7) but not where it was omitted (lanes 4, 6 and 8). This fragment is not ampli®ed in cells transfected with empty vector (lane 9). Lane M shows DNA size markers corresponding to 2176, 1766, 1230, 1033, 653, 517, 453, 394, 298, 234, 220 and 154 base pairs. (b) shows parallel PCR reactions in which primers speci®c for GAPDH were included as an internal control. Lane 1 shows a control PCR reaction in which no DNA was added. GAPDH is ampli®ed in cells transfected with either wt-BRCA1, BRCA1-D329 ± 435, BRCA1-D379 ± 408, or empty vector only in samples where reverse transcription is performed (lanes 2, 4, 6 and 8, respectively), but not where it is omitted (lanes 3, 5, 7 and 9, respectively) artifact. Additional experiments showed that deletion of amino acids 329 ± 435 as well as the minimal domain de®ned above (amino acids 379 ± 408) resulted in a loss of growth suppression. Taken together, these data suggest that a BRCA1 domain between amino acids 329 and 435 is essential for growth suppression. Notably, this essential domain can be further de®ned to a region that has been shown to be a target for phosphorylation.
The work described here provides evidence for a kinase that associates with and phosphorylates BRCA1. The role of this kinase in regulation of BRCA1 has not been completely de®ned. However, our initial studies, particularly the deletion studies which show that growth suppression is tied to the region of phosphorylation, suggest that this kinase may play an important regulatory role. Further work is aimed at puri®cation of the kinase and de®ning the exact site(s) of phosphorylation. Through this work we hope to identify at least one regulatory pathway in which BRCA1 participates. Understanding this pathway may provide further insight into the role that BRCA1 plays in cancer development or more knowledge about the speci®c developmental pathways that are operative in endocrine tissues.
Materials and methods

Expression and isolation of BRCA1 peptides
cDNA encoding various domains of BRCA1 were cloned into pVL 1393 either alone or downstream and in frame with the gene encoding S. japonicum glutathione-Stransferase (GST). These baculoviral transfer plasmids were introduced into Sf9 cells alone with wild-type AcMNPV (Invitrogen cat #B825-03) and recombinant viruses were isolated 72 h later. Sf9 cells were infected with plaque puri®ed viral stocks at an moi of 5, harvested 48 h later, and subsequently lysed in lysis buer (25 mM HEPES (pH=7.5), 150 mM NaCl, 0.5% NP-40, 1 mM Pefabloc-SC (Boehringer-Mannheim cat #1429-876), Complete Protease Inhibitor Cocktail (Boehringer-Mannheim, cat #1697-498)). Crude lysates were centrifuged at 16 000 6 g for 5 min and the resultant supernatant was incubated with glutathione-Sepharose 4B (Pharmacia, cat #17-0756-01). GST fusion proteins, which were bound to glutathione-Sepharose 4B, were washed with lysis buer and used in kinase assays as described. Proteins produced without GST tags were puri®ed on Protein G-agarose (Boehringer-Mannheim cat #1243-233) bound with a murine monoclonal antibody raised against amino acids 499 ± 511 of BRCA1. The monoclonal antibody was raised by Magda Gutowski at Eli Lilly.
Kinase assays
Proteins for kinase reactions were bound to glutathioneSepharose or to protein G-agarose, incubated in lysis buer with 10 mM MgCl 2 , 1 mM dithiothreitol (DTT), and either 1 mCi/mL of [ 32 P]-or [ 33 P]-g ATP at 328C for 30 min. The resin-bound complexes were washed with lysis buer then solubilized from the resin by boiling in 40 mM Tris-HCl, 1% SDS, 50 mM DTT, 7.5% glycerol, 0.015% bromophenol blue, pH=6.8, and resolved on 8 ± 16% polyacrylamide gels (Novex cat #EC6045). Phosphorylation was analysed by autoradiography.
Some fragments of BRCA1 were treated with SDS prior to their use in phosphorylation reactions. In these situations, the proteins were incubated in lysis buer containing 0.1% SDS for 30 min. The proteins, which were bound to either glutathione-Sepharose or protein G-agarose, were washed several times with lysis buer without SDS and then incubated with radiolabeled ATP as described above. In some cases, SDS-washed proteins were incubated with crude lysates from various cell lines. These cell lysates were prepared in lysis buer as described above and were incubated with the SDS-washed BRCA1 fragments for 30 min. After incubation with the crude lysates, the BRCA1 peptides were washed with lysis buer and subsequently incubated with ATP. Experiments evaluating phosphorylation by speci®c kinases including cAMPdependent kinase (PKA), protein kinase C (PKC), casein kinase II (CKII), SAPK/Jun kinase, and cyclinE/cdk2 were performed similarly. Speci®cally, BRCA1 fragments were washed with SDS (to remove endogenous kinase activity) then washed in lysis buer without SDS and subsequently incubated with kinase for 30 min. The Sepharose bound fragments were again washed with lysis buer and then incubated with ATP as described above. PKA (cat #1529307), PKC (cat #145965) and CKII (cat #1500767) were purchased from Boehringer-Mannheim. The concentrations of each kinase used were 0.3 units/mL, 0.005 units/mL and 0.5 units/mL, respectively. SAPK/Jun kinase was purchased from Upstate Biotechnologies. CyclinE/cdk2 was provided by R Nagaraja Rao from Eli Lilly.
Phosphatase treatment
Proteins to be treated with phosphatase were bound to glutathione-Sepharose and washed in AP reaction buer (5 mM Tris-HCl pH=7.4, 25 mM KCl, 10 mM MgCl 2 ). The resin-bound proteins were then incubated with bovine intestinal mucosa alkaline phosphatase (Sigma cat #P-8647) for 30 min at 308C at a concentration 12.5 units/mL. The alkaline phosphatase was activated just prior to its use by a 30 min incubation at room temperature in 5 mM Tris-HCl pH=7.4, 25 mM KCl, 0.5 mM MgCl 2 .
Analysis of phosphorylated peptides
Following phosphatase treatment, GST-BRCA1 peptides were washed once with 50 mM Tris-HCl (pH=7.5), 150 mM NaCl 2.5 mM CaCl 2 and then incubated with 0.02 units of thrombin for 2 h (room temperature) to remove the GST. The BRCA1 fragments were then phosphorylated in vitro as described above and puri®ed by HPLC using a Vydac C18 reverse phase column and a 0 ± 80% acetonitrile gradient. The puri®ed fragments were lyophilized and resuspended in 50 mM Tris-HCl pH=8.0. Resuspended fragments were digested with trypsin at 5 mg/ mL for 3 h at 378C and the resultant peptides were puri®ed by HPLC. Samples from each fraction were removed and analysed for the presence of 32 P or 33 P radiolabeled by scintillation counting.
Cell labeling and analysis of phosphorylation
Labeling of cells with 32 P was accomplished by incubating cells with 1.0 mCi of 32 P-orthophosphate (NEN cat # NEX-053H) for 4 h in phosphate-free medium. These cells were then harvested and lysed in lysis buer plus 50 mM NaF, 10 mM sodium pyrophosphate, and 1 mM sodium vanadate. Lysates were clari®ed by centrifugation at 16 0006g for 5 min and then immunoprecipitated with control IgG or a monoclonal antibody speci®c to BRCA1. Immune complexes were captured using Protein G agarose, and washed four times in lysis buer. Captured complexes were solubilized and analysed by SDS ± PAGE as described above. Some precipitations were done using cells transfected with fragments of BRCA1. These fragments were expressed in these cells as fusion proteins containing SProtein (ETAAAKFERQHMDS) at their N-termini. These protein fragments were captured from radiolabeled cell lysates using S-agarose (Novagen, cat #69704-1).
Transfected cell lines
WI-38 lung ®broblasts (VA13 subline) were transfected with a doxycycline-repressible vector construct (O'Brien et al., 1997) containing a S-Protein-BRCA1 fragment encoding amino acids 329 ± 435 from BRCA1. Expression from this construct is repressed when cells are grown in the presence of 10 ng/mL of doxycycline. Cell lines which had integrated the doxycycline-repressible BRCA1 construct were isolated by survival in 200 mg/mL of hygromycin B. These transfected cells were used for the phosphorylation studies described above. In addition, A2780 ovarian carcinoma cells were transfected with the identical doxycycline-repressible construct and used for the cellbased phosphorylation studies 2 days following their transfection. Transfection of the cell lines was accomplished using Lipofectin (WI-38) or Lipofectamine (A2780) following the procedures outlined by the supplier (GIBCO BRL).
Growth suppression assays
A 5' AvrII site was introduced into a construct containing full-length human BRCA1 which then facilitated the cloning of BRCA1 into pRc/RSV (Invitrogen) between SpeI and NotI. This plasmid construct, as well as versions containing deletions in BRCA1, were transfected into A2780 using Lipofectamine. Two days later, G418 was added to the growth medium at a concentration of 400 mg/ mL and colony formation was scored 2 weeks later. Control cells were transfected with a pRc/RSV plasmid lacking BRCA1.
Detection of expression of BRCA1 following transfection
Expression of wt-BRCA1 and the deletion mutants was assessed in transfected A2780 cells by RT ± PCR. Speci®cally, cells were harvested and total RNA was prepared using the SNAP Total RNA Isolation Kit from Invitrogen (cat #K1950-01) which included a treatment with DNAse to remove contaminating DNA. The SuperScript Preampli®cation System (GIBCO, cat #18089-011) was used to reverse-transcribe the RNA into DNA using oligo-dT as a primer. Speci®c detection of the transfected version of BRCA1 cDNA was accomplished using an oligonucleotide speci®c for the RSV-driven transcript as a 5' PCR primer (5'-TCAATGGAAGAAACCACCAAG-3') in conjunction with a BRCA1 speci®c oligonucleotide as a 3' primer (5'-TCTAGATGCATGCTCGAGCG-3'). PCR reactions involved 35 cycles; consisting of 30 s of denaturation at 948C, 30 s of annealing at 578C and 30 s of extension at 728C. Parallel PCR reactions using samples which had been mock reverse-transcribed were included as a control for evaluating the presence of contaminating DNA. GAPDH served as an internal standard for the PCR reactions.
Construction of BCRA1 deletions
Deletion of suspected regions of phosphorylation were created using the`QuickChange' site-directed mutagenesis kit from Stratagene (cat # 200518) . The D329 ± 435 deletion was created using 5'-cataacagatgggctggaagtaaggaaacatgtcctcatgaggctttaatatgtaaaagtg-3' and 5'-cacttttacatattaaagcctcatgaggacatgtttccttacttccagcccatctgttatg-3' as mutagenic oligonucleotides. The oligonucleotides used for the D379 ± 408 deletion were 5'-gatgttccttggataacactaaatagcagcgtagctgatgtattggacgttctaaatgag-3' and 5'-ctcatttagaacgtccaatacatcagctacgctgctatttagtgttatccaaggaacatc-3'. All deletions were con®rmed by sequencing.
